From lab to patient: Why European biotech is at a crossroads
Gunnar De Winter
From lab to patient: Why European biotech is at a crossroads
Innovation only succeeds when it demonstrably creates value for both patients and the healthcare system. How can biotech and pharmaceutical players design their R&D strategies so that medical innovation reaches patients faster, more precisely, and in an affordable way? An interview with Jérôme Van Biervliet and Frank Hulstaert.
This article first appeared in Dutch in Kompas Healthcare (author: Lieven Desmet).
Belgium has long ranked...